High doses of favipiravir combat SARS-CoV-2 in hamsters
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
List view / Grid view
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
A team has said that inhibiting the factor D protein could prevent SARS-CoV-2 from turning the immune system against healthy cells.
Researchers have found that the surface of SARS-CoV-2 can take on at least 10 different structural states when in contact with ACE2.
Breaking down or slowing the production of a hyaluronan jelly which builds up in the lungs of some severe COVID-19 patients could reduce respiratory distress and prevent death.
Researchers have posited that SARS-CoV-2 could be combatted by sofosbuvir, in combination with other antivirals such as remdesivir.
The nitric oxide treatment used during the 2003 SARS epidemic could be used as an antiviral against SARS-CoV-2, researchers say.
Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.
Researchers found that the SARS-CoV-2 infection activates the NF-κB pathway, driving unchecked inflammation that contributes to total organ failure in COVID-19 patients.
The C5 compound targets the frameshifting element that allows SARS-CoV-2 to effectively replicate and marks the genome for destruction to stop the infection spreading.
New research has shown that MAIT cells are strongly activated in people with moderate to severe COVID-19 disease.
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
A new interactive map of the surface of SARS-CoV-2, featuring the Spike, Envelope and Membrane proteins, has been released for researchers to use.
Researchers have identified two molecules that explain why children experience COVID-19 differently to adults.
A pocket in the SARS-CoV-2 Spike protein has been discovered by researchers, who say it could be a drug target for COVID-19.
SARS-CoV-2 entry into human cells is dependent on heparan sulfate and disrupting this interaction using heparin reduces infectivity of the coronavirus, find scientists.